Lisata Therapeutics Inc (LSTA)

[akasidney86]

Wow, that's a great report. Lower costs, increased income, but most importantly a really broadsided assault on multiple fronts from, diabetes through melanoma and other cancers and all via personalized molecular meds, with most studies and trials paid for by others. The association of an investigational immunotherapy company with a known and established manufacturer of same was what brought me to CLBS (NBS) in the first place, and my original opinions have only been reinforced by this conference call.

IMO people got scared by the name change and the apparent 'dropping' of the ischemia program, but the first is irrelevant and the second, given the news of the Japanese programs in development not correct, so I'd guess that the price should return to the $2-4 range within a year or less. The best news of all was that the interest in the melanoma PIII is 2-3 times what they expected (tumor samples supplied from docs), so filling that study shouldn't be difficult.